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utonomy, at least in the
context of our framework
for patient decision making,
is under siege. The attack is coming
from at least two quarters. Some
believe that patients have taken the
autonomy model too far, demanding
certain treatments that physicians
would not recommend. This has
occurred in legal cases like Wanglie,1
Gilgunn,2 and Baby K3 where
physicians believed that continued
life-sustaining treatment for the
patient was “futile,” or medically
inappropriate, and patients or their
family members demanded continued
treatment. But, it also occurs in other
medical settings, for example, where
pregnant women demand c-sections
or assertive parents demand an
antibiotic for their child’s sore throat.
The second onslaught comes from
a wholly different perspective, that
patients are uncomfortable making
complex medical treatment decisions
for themselves, especially when their
choices are fraught with uncertainty.
These patients, or their family
members, are overwhelmed by the
information and the responsibility.
Most attention in the bioethical
and medical literature has focused
on the first of these assaults; I want
to focus on the latter. There is
considerable support for the view

that patients who are ill and fragile
may not want to make their own
treatment decisions. In his book,
The Practice of Autonomy: Patients,
Doctors and Medical Decisions,4 law
Professor Carl Schneider amasses
considerable data on this point. For
example, he cites a study by Ende
et al.,5 who presented 312 patients
in a primary care clinic with a series
of vignettes representing various
levels of illness severity and asked
them in each scenario, on a scale
from 0 to 100, to indicate their desire
for making their own treatment
decision. The mean score for the
study population was 33.2, indicating
that patient preferences for decision
making were quite weak. In addition,
they found that as patients were
asked to consider increasingly severe
illnesses and as they got older their
desire to make decisions themselves
declined.
Schneider also presents data that
patients are willing to cede some
of their autonomy when they are
incompetent, even if they have
expressed preferences for or against
various forms of treatment. He cites
the work of Sehgal and colleagues6
who asked 150 dialysis patients “how
much leeway their physician and
surrogate should have to override
Cont. on page 3
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NETWORK NEWS
MARYLAND HEALTH
CARE ETHICS
COMMITTEE
NETWORK (MHECN)

THE METROPOLITAN
WASHINGTON
BIOETHICS
NETWORK (MWBN)

HECN is sponsoring a
panel discussion and
dinner,
Money & Medicine: Bedside Ethics
of the Medical Marketplace, from
4:30 p.m. to 7:15 p.m., at Greater
Baltimore Medical Center on January
30, 2007. This symposium will
provide an opportunity for health
care providers and ethics committee
members to explore the topic of
health care cost as it relates to an
individual clinical case. Speakers
include Marion Danis, MD; Rebecca
Elon, MD; MPH, Diane Hoffmann,
JD, MS; and Jack Schwartz, JD.
MHECN will offer its biannual
basic ethics education conference
for health care ethics committee
members in the summer of 2007,
most likely in June. This will be a
one-day conference geared toward
health care ethics committee
members.
MHECN is pleased to announce
that the Johns Hopkins Berman
Institute of Bioethics (formerly
the Phoebe R. Berman Bioethics
Institute at Johns Hopkins) has joined
MHECN as an affiliate member.
We welcome their support and
involvement.
Contact MHECN at (410) 706-4457;
e-mail: MHECN@law.umaryland.
edu.

WBN members took
advantage of several local
ethics educational
opportunities at Georgetown
recently. It continues its guardian
training sessions with the D.C.
Superior Court Probate Division.
For more information about
MWBN, contact Joan Lewis,
Executive Director, 202-895-9408,
e-mail jlewis@iona.org.

M

MHECN Program Coordinator:
Anita J. Tarzian, PhD, RN.

M

Richmond
Bioethics
Consortium (RBC)

A

t the VAST (Virginia
Association of Science
Teachers) conference
in November, RBC presented
information about a grant project
to encourage science teachers
to address bioethical issues in
their classrooms. RBC is offering
$500 "classroom mini-grants" for
biology and life sciences teachers
to introduce the topic of bioethics
to students in grades 6-12. RBC
recently generated new mission and
vision statements as a result of its
strategic planning process.
For more information about RBC,
contact Gloria Taylor, RN, MA,
CPTC, RBC President, at taylorgj@
unos.org.

Choosing Paternalism?
Cont. from page 1

[their] advance directive if overriding
were in [their] best interests.” The
patients varied greatly in their
responses: 39% said “no leeway;”
19% said “a little leeway;” 11%
said “a lot of leeway” and 31% said
“complete leeway.”
Articles confirming this
perspective have also appeared in
the popular press. A little over a
year ago, a New York Times article,
entitled “Awash in Information,
Patients Face a Lonely, Uncertain
Road,”7 described the anguish and
abandonment patients feel when
forced to make difficult medical
decisions. The article described the
case of a 39 year old patient with
ovarian cancer that had metastasized
to her liver. She was asked to
decide whether to undergo a novel
chemotherapy regimen about which
five oncologists disagreed. When she
asked her doctor what she should
do he said he didn’t know, that she
would have to make the decision
based on her own values. The patient,

“bald, tumor-ridden and exhausted
from chemotherapy was reeling.
‘I’m not a doctor!’ she shouted, ‘I’m
a criminal defense lawyer! How am
I supposed to know?’” The story
illustrates the frustration, anxiety,
and loneliness of being a “modern
patient” attempting to cope with
medical uncertainty.
When patients are competent,
ideally they and their physicians
engage in shared decision-making,
where there is give and take between
both and neither the autonomy nor
the paternalism model dominates.
However, once a patient lacks
competency, the opportunity for
shared decision-making may
be gone (at least as between the
patient and the physician). In those
circumstances, how should we
respond?
If we are persuaded by the studies
and anecdotes indicating that at least
some portion of our population is
not comfortable with the “autonomy
model,” should we change our legal

Maryland Patients Given Advance
Directive Flexibility
During the 2006 Legislative Session, the Maryland General Assembly
passed several amendments to the Health Care Decisions Act. Among those
changes was a provision in the advance directive form allowing patients to
specify how strictly they want their stated preferences followed. The model
form includes a provision allowing the individual completing the form to
choose one of the following options:
1. I realize I cannot foresee everything that might happen after I can no
longer decide for myself. My stated preferences are meant to guide whoever
is making decisions on my behalf and my health care providers, but I
authorize them to be flexible in applying these statements if they feel that
doing so would be in my best interest.
2. I realize I cannot foresee everything that might happen after I can no
longer decide for myself. Still, I want whoever is making decisions on my
behalf and my health care providers to follow my stated preferences exactly
as written, even if they think that some alternative is better.

framework for health care decision
making, in particular our framework
for making decisions about lifesustaining treatment for patients
lacking decision-making capacity?
Certainly, we cannot abandon
autonomy; for many people the
autonomy model is still sacrosanct.
Rather, we need a model that
allows for flexibility – for both
autonomy and paternalism. There
are, however, obstacles to choosing
paternalism once a patient lacks
decision-making capacity. One
reaction would be to give patients
an option to “undermine” their own
autonomy, i.e., to autonomously
choose paternalism. At least one
state, Alabama, has made it easier for
patients to give up some autonomy
by modifying the state’s advance
directive form to allow patients to
indicate whether they want their
wishes strictly followed or prefer
that their proxy do what he or she
thinks is best, even if it means doing
something different from what the
patient has specified in the form.8
The Maryland legislature recently
made a similar change to its advance
directive form.9
Another response would be to
make it easier for patients to appoint
their physician as their health care
agent. Many states actually prohibit
this, arguably due to concerns about
physician paternalism and possible
conflicts of interest.10 Ironically,
these laws replace physician
paternalism with state paternalism.11
In New York, for example, health
care proxy instructions provide that
you can appoint your physician as
your proxy but then he/she cannot
also be your treating physician.12
In Maryland, a physician can be
appointed as a health care agent
Cont. on page 10
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Clinical Cancer Research: Can the
Phase I Trial ever be ethical?
Although MHECN does not focus
specifically on research ethics, there
may be times when a physician is put
in the role of advising a patient as
to whether he or she should enroll
in a Phase I clinical trial. This
article, by Laurie Lyckholm, an
Associate Professor and Program
Director of Hematology/Oncology
and Palliative Medicine at Virginia
Commonwealth University School
of Medicine, explores this topic
and provides a helpful framework
for physicians confronted with this
question.

I

am not a classical philosopher by
trade or training, but a medical
oncologist and medical school
professor who trained in clinical
medical ethics. One of the most
compelling reasons for such training,
which was not regularly offered in
medical school in the 1980’s, was
to be able to ethically navigate my
patients and myself through the
complex challenges that arise when
enrolling a patient with cancer in a
clinical trial.
It is helpful to understand that
there are four phases of clinical
trials, each with its own particular
set of ethical challenges. But the
Phase I trial is most vexing to a host
of bioethicists and researchers alike.
Phase I cancer therapy trials
involve the use of an experimental
agent or experimental use
of conventional agents, or a
combination of the two. These
trials are aimed at cancers that have
become resistant to conventional
agents, or those for which there
is minimal effective treatment or
cure, such as advanced melanoma,
and cancers of the kidney, liver/gall
bladder, and brain, among others.
 Mid-Atlantic Ethics Committee Newsletter

The experimental agents have had
some success in preclinical, usually
animal experiments, so they are
now being tried in humans. The
chance they will shrink or at least
stabilize the cancer is somewhere
between 5 and 40%.
The primary goal of the Phase I
trial is to test the experimental agent
for side effects and dose limiting
toxicity, with efficacy against the
cancer a distant secondary goal.
Phase I trials are not limited to
cancer research, and the same
principles may be generally applied
when researching other diseases.
It is the closest one gets to the
patient being, as many of mine
have correctly said, “a guinea pig.”
Despite the fact that patients, or
subjects, as they are called when
they enter a clinical trial, are told
that the goal is not therapeutic,
surveys have shown that many
patients believe the reason they are
participating in the Phase I trial is to
cure their cancer.
Testing new therapies on patients
to see how toxic they are … does
that sound ethical? It has not
been that long since the Tuskegee
Syphilis Study, Willowbrook
hepatitis experiments or the
atrocities performed in the name of
science by the Nazis during WWII.
Safeguards, beginning with the
Belmont Report and the Nuremburg
Code, and creation of institutional
review boards with oversight of
the protection of human subjects,
have been placed to prevent such
practices from ever occurring again.
With those protections, toxicities
are monitored very closely during
Phase I trials, not only since that
is the focus of the study, but also
as a way to protect the patient
from undue harm. Patients who are

considered too vulnerable, such as
those who are mentally challenged,
prisoners, and others, are excluded
from the studies. And consent forms
are extensive and written to make
sure that potential study subjects
receive the most comprehensive
information possible (which may
actually be a drawback, in the form
of information overload).
Those who feel that phase I
studies may be conducted ethically
use two main arguments; one, that
if patients give their consent, after
being informed extensively of the
risks, benefits and the purpose of
the trial, then it is their autonomous
decision to do so. Secondly, it is
arguably ethical to offer possible
treatments that may slow the
cancer and may also advance the
science of cancer treatment overall.
Toxicity and study outcomes
are carefully monitored, and the
study is discontinued if there is
excess toxicity or excess mortality
attributable to the agents being
studied.
On the con side, there are
arguments that informed consent
is not really possible in these
circumstances because the patients
are vulnerable and desperate,
frightened by the specter of
advancing disease. In addition, the
complex nature of both the study
designs and the treatment itself does
not allow for full understanding
by most patients, even with the
most thorough disclosure. After all,
thorough disclosure does not equal
thorough understanding.
There are also competing interests
for the physician-scientist—the
patient under his or her care and
that of scientific as well as personal
professional advancement. The
conflict between patient care and
Cont. on page 10

Is Your Ethics Committee Competent to
Consult? What are Benchmarks of Success?

A

ccording to the American
Society for Bioethics and
Humanities’ Core
Competencies for Health Care
Ethics Consultation (1998), at
least one person in your facility’s
ethics committee (EC) should have
advanced expertise in each of these
areas:
• Moral reasoning and ethical
theory
• Common bioethical issues
and concepts
• Health care systems
• Clinical context
• Local health care
organization’s policies,
including those on:


Advance Directives



Organ Donation



Goals of Care



Patients with Long Term
Stays



Patient Consent



Ethics Committee Access



HIV Testing

Interdisciplinary
Collegiality




Reproductive Services

•Cultural and religious beliefs
of those served by the facility
•Relevant codes of ethics and
professional conduct guidelines
•Relevant health law
In addition, Anita Catlin, DNSc,
FNP, FAAN, Ethics Consultant and
Associate Professor of Nursing
at Sonoma State University in
California, recommends the

following benchmarks to measure
the competence of your committee
(Catlin, 2006, p. 9):
• Ethics should be proactive, not
reactive. The EC should work
to create or improve policy that
might mitigate continual response
to individual dilemmas.
• The outcomes of the ethics
committee should be translated
into demonstrable outcomes.
• The EC has representation from
all constituencies in the hospital,
with co-chairs representing the
largest facility constituency (e.g.,
nursing).
• The EC is well trained by a
leader in ethics who has received
formal ethics education.
• EC members are known to
facility staff, are trained in
consultation, and are available
for immediate discussions of
minor issues, and can call for a
full committee consultation when
needed.
• There is a standard recorded
format for the ethics consultation.
The form is kept and used
for data collection, trend
identification, and educational
purposes.
• Members of the facility know
how to contact the EC, and do so.
There are materials available on
the units for reference.
• Ethics rounds are made on the
various shifts. There is an ethics
training binder on every unit.
• Members of the EC belong to
and attend the annual meeting
of the American Society for

Bioethics and Humanities. Each
member has a copy of the Core
Competencies for Health Care
Ethics Consultation.
• Members of the EC receive
and read health care ethics
journals, such as the Journal of
Clinical Ethics; the Hastings
Center Report, HEC Forum,
or the Cambridge Quarterly of
Healthcare Ethics.
• Physician members have
received End-of-Life Physician
Education Consortium (EPEC),
or comparable, training.
• Nurse members have received
End-of-Life Nursing Education
Consortium (ELNEC), or
comparable, training.
• Members of the staff are aware
of the Nursing and Medical
Codes of Ethics and Patient’s
Bill of Rights, and care is
delivered accordingly.
References:
Catlin, A. (2006), Plan to Bring Ethics
Committee to Magnet Standards, Submitted to
Kaiser Santa Rosa Organization, Santa Rosa,
California, September 15, 2006.
American Society of Bioethics and
Humanities (1998), Core Competencies for
Health Care Ethics Consultation. Glenview,
Illinois: American Society of Bioethics and
Humanities. Order online at www.asbh.org.
American Medical Association (AMA)
Council on Ethical and Judicial Affairs
(2006), Code of Medical Ethics 2006-2007:
Current Opinions with Annotations (Code
of Medical Ethics). American Medical
Association.
American Nurses Association (2001), Nursing
Code of Ethics with Interpretive Statements.
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FOCUS on
the Center for Ethics
at the Washington Hospital Center

T

he Center for Ethics at the
Washington Hospital Center,
founded by Dr. John Lynch, is
credited with being one of the oldest
hospital ethics programs in the
country. It evolved from an ethics
committee established in 1982 to a
program housed in the Hospital’s
Department of Pastoral Care, and
then developed into a separate
department in 1992. Its current
director is Nneka Mokwunye, a PhD
candidate at Howard University.
Two other bioethicists on staff are
Evan DeRenzo, PhD and Daria
Grayer, MA. Dr. Lynch is still an
active member of the Center and is
the current Chair of the Hospital’s
ethics committee.
The Center provides consultations
in clinical and research practice,
and also coordinates continuing
education programs in bioethics,
develops and critiques institutional
hospital policy, and develops and
implements independent research on
biomedical issues. The Center runs
a 35-member bioethics committee
that has three subcommittees:
policy, education, and consultation.
A new venture for the Center is
the publication of The Journal of
Everyday Clinical Ethics. The
Journal is scheduled to be released
January 2007. (For further details on
submissions please email ethics@
medstar.net.)
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The Center’s mission is to
“develop, promote and maintain
the highest standards in ethical
knowledge and awareness in all
aspects of clinical practice.” In
October, as part of its own education
mission, the Center hosted a
Bioethics Awareness Week (October
16-20, 2006). Events included
opportunities to meet the members
of the ethics committee and discuss
bioethics topics such as medical
futility; an advance directive fair
and information seminar; women’s
awareness workshops; “breakfast
with bioethics” to discuss clinical
ethics case studies; and “ask the
ethicist” sessions where staff
and community members could
bring their own ethical issues for
clarification or discussion. During
the advance directive fair the Center
staff assisted over 150 participants
in completing advance directives
and disseminated numerous
information packets for participants
to give to their family members and
friends.
The week long educational
program included a focus on
HIV awareness and prevention
specifically on disclosure of HIV
positive mothers to their partners.
The goal was to help these mothers
obtain the necessary assistance for
protecting their babies from HIV

transmission. “Breakfast with
Bioethics” and “Ask the Ethicist”
sessions were a time for staff to
ask any questions they had about
these issues, in particular. The
ability to discuss one-on-one with
the bioethicists gave the staff a
mechanism to release any moral
distress they were feeling and
find comfort in knowing that their
concerns were being addressed.
The Center will be holding
Bioethics Awareness Week
annually.
Has YOUR facility instituted a
special program or educational
endeavor in bioethics that you
would like to share? Let us know
by emailing us at MHECN@law.
umaryland.edu, or calling (410)
706-4457.

Case Presentation
One of the regular features of the
Newsletter is the presentation of
a case considered by an ethics
committee and an analysis of the
ethical issues involved. Readers are
both encouraged to comment on the
case or analysis and to submit other
cases that their ethics committee has
dealt with. In all cases, identifying
information about patients and
others in the case should only
be provided with the permission
of the patient. Unless otherwise
indicated, our policy is not to
identify the submitter or institution.
Cases and comments should be sent to
MHECN@law.umaryland.edu, or
MHECN, the Law & Health Care
Program, University of Maryland
School of Law, 500 W. Baltimore St.,
Baltimore, MD 21201.

CASE STUDY FROM
A D.C. HOSPItal

M

s. Casey is a 32 year old
woman who delivered a
full term infant at a D.C.
hospital. As she is HIV positive,
the team begins teaching her about
the antiretroviral regimen her infant
will be sent home with. Ms. Casey
discloses to her physician that her
husband does not know that she
is HIV positive, and she does not
intend to tell him. There is reason
to believe that Ms. Casey does
not intend to give her infant the
antiretroviral drugs prescribed, and
may not be taking antiretrovirals
herself, for fear her husband will
find out about her HIV status. The

physician tries to convince Ms.
Casey of the importance of taking
antiretroviral medications and of
telling her husband about her HIV
status, but she is adamantly opposed
to doing so. She tells the physician
and nurse involved in her care that if
someone informs her husband about
her HIV status, she will sue for
privacy violation. The nurse requests
an ethics consult. She is concerned
about the rights of the husband and
the welfare of her patient's infant.

RESPONSE FROM A
bioethicist
and ethics
consultant

T

he ethical dilemma of this
case rests on the collision of
the principles of autonomy,
beneficence, and nonmaleficence.
These principles are at play in the
following ways:
• the autonomy of the mother
to request that her HIV status
remain private and confidential,
• the autonomy of the father to
have any relevant information
that directly relates to his well
being presented to him,
• beneficence towards the mother
to protect her from the negative
consequences of her HIV status
being divulged,
• beneficence towards the father
by allowing him to protect

himself from any further
exposure to HIV,
• beneficence towards any other
person who the father may infect
if he is HIV positive, due to not
knowing his own HIV status,
• beneficence towards the baby
in providing necessary medical
interventions to prevent HIV
infection,
• nonmaleficence to the mother by
avoiding harm that would ensue
if her privacy and confidentiality
were violated if her HIV status
were to be disclosed,
• nonmaleficence to the father by
avoiding harm that might ensue
if he were not informed about
his wife’s HIV status and his
own risk of being infected, and
• nonmaleficence toward the baby
by preventing HIV transmission
through preventive treatments,
which is less likely to happen if
both parents are not informed
of the medical appropriateness
of the antiretroviral drugs for
prevention of transmission.
It is the ethical duty of the hospital
to provide appropriate care for its
patients. In this case, the baby and
the mother are both patients of the
hospital. In an effort to protect the
baby, the physicians have the ethical
duty to inform both parents of the
risks of exposure to HIV and the
therapies needed to minimize or
eliminate transmission. If, in having
Cont. on page 8
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Case Presentation
Cont. from page 7

this conversation, the father deduces
that the HIV exposure comes from
his wife, then that it is a side effect
of the informed consent process.
Ethically, there is a strong
argument that the patient has a moral
obligation to inform her husband
about her HIV status. The physician
can do his or her best to convince the
patient to do so. However, opinions
differ about whether a physician’s
primary duty is to protect the
patient-provider relationship by not
breaching a patient’s trust (i.e., by
informing a sexual partner about
positive HIV status), or to protect
a third party who may be at risk of
harm. For example, some argue that
more harm may come by requiring
physicians to breach patient
confidence in such situations, since
this may erode patient-provider
trust and lead to patients avoiding
medical care.
While clinicians are obligated to
warn others of known direct harms
(for example, a homicidal patient
divulges a plan to his psychologist
to kill his girlfriend, as in the famous
Tarasoff case), there are differing
opinions about whether or not

divulging a positive HIV status to
a current or former sexual partner
constitutes direct harm. States
have different laws about clinician
disclosures in such situations. In
the District of Columbia (D.C.),
the physician cannot inform the
patient's husband that he has been
exposed to HIV or suggest that
he be tested and protect himself
from further exposure. (In contrast,
Maryland law allows, but does
not obligate, a physician to make
such a disclosure.) However, D.C.
law allows the physician to inform
a child’s father of all relevant
information regarding the welfare
of the child, and this supersedes the
right of the mother to keep her HIV
status private.
The physician should inform the
mother that relevant information
to provide appropriate care for
the baby (including the need for
ART medication to prevent HIV
transmission) will be shared with
her husband. Once the baby is born,
all information relevant to provide
appropriate treatment for the baby
must be divulged to both parents.
The mother may sue the hospital

for violating her right to privacy.
That is a price the hospital has to
pay to fulfill its ethical obligation
to provide adequate care to the
baby, which in this case trumps the
obligation to protect the mother’s
privacy regarding her HIV status.
As the ethics consultant for the case,
my recommendation would be to
inform the mother that the health
care team will provide all relevant
medical information about the care
of the infant to both parents, and
the baby will not be discharged
until this conversation has taken
place and there is agreement to
follow the regimen to minimize HIV
transmission. I would have social
services continue to follow the case
and child protective services keep
an eye on the situation to make sure
the baby is getting the necessary
treatments.
Nneka Mokwunye
Ph.D. Candidate, M.A.
Director, Center for Ethics
Washington Hospital Center

EDUCATIONAL OPPORTUNITY! 3-Class Ethics Course at
INOVA Health System, Falls Church, VA
Thursday, February 8, 2007
Ethics in Everyday Clinical Practice
Wednesday, April 11, 2007
Current Controversies in Healthcare Ethics
Friday, May 11, 2007
Ethical & Psychosocial Management of the Patient and Family Identified as Difficult
For more information, contact Patti O’Donnell, PhD, Director, Center for Ethics,
Inova Health System at 703-321-2658 (phone) or patricia.odonnell@inova.com.
To register, call Inova Teleservices at 703-205-8384.
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Case Presentation
Response from a
nurse attorney

T

his case is about the welfare
of the child. The mother’s
statements have given rise
to a reasonable probability that the
child will not get the necessary
medications and that universal
precautions will not be observed.
Immediate and life-threatening harm
to the child is likely.
If I were hospital counsel I
would call the Emergency Judge
and Petition for the appointment
of a Temporary Guardian of the
Child. I would allege parental
neglect. An immediate hearing
on the Emergency Petition would
be scheduled at the hospital. The
parents would attend the hearing
during which only the child’s
medical status would be discussed.
Any available lab values or other
information about the child which
would justify the need for the
antiviral regimen would be revealed.
The doctors may ultimately just
state that they have reason to believe
the child has had a significant HIV
exposure. The husband is likely to
deduce the source of the child’s need
for antiretrovirals without being
directly told that the wife is HIV
positive. If he should ask outright,
the hospital staff could suggest that
he discuss this with his wife.
After the disclosure of the
child’s status (and most likely the
mother’s HIV positive status),
there may be no need for further

court intervention. The mother
or father may agree to administer
the medications. If the mother is
uncooperative and continues to resist
medicating the child, taking her own
medications and observing universal
precautions, I am confident that
a D.C. judge would appoint a
Guardian of the child and order the
antiretroviral treatment on a parens
patriae theory. The husband/father
could be appointed depending on his
conduct at the hearing. The judge
might order ongoing intervention
by a child welfare agency. In
any event, this family is going to
need a lot of support and ongoing
monitoring once the child’s medical
status is revealed.
An emergency Petition is exactly
the action I have taken in several
cases in which the parent of a minor
child/infant has refused blood
transfusions for religious reasons.
In those cases the parents had an
arguably valid reason for refusing
the treatment. Here, the mother’s
reason is somewhat understandable,
but is secondary to considerations
of the child’s welfare. If she is
concerned about domestic violence
or abandonment of financial support
by the spouse, the wife should be
offered access to any available
resources. The husband will discover
her HIV positive status sooner
or later. This information is best

delivered in the relative safety of
the hospital with readily available
information and support for the
family.
The father of the child has a right
to know about the child’s medical
status and a right to protect himself.
The hospital has an ethical duty to
advise him of the child’s medical
status and the need to use universal
precautions when caring for the
child, both for the child’s welfare as
well as his own. Unless the hospital
provides this information to both
parents, the child cannot be safely
discharged.
The hospital risks the wife’s
lawsuit for invasion of privacy.
However, this risk is far less than
the risk to both the welfare of the
child and the husband. The child
is likely to sustain harm if deprived
of reasonable medical treatment
and could sue the hospital. The
hospital has no rational basis to
permit withholding of information
about the child’s medical needs from
the father. One parent has no greater
rights to control this information
than the other parent, assuming there
are no questions about paternity.
Andrea Sloan, R.N., Esq.
Private Practice
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Choosing Paternalism?
Cont. from page 3

but only if he/she is not the owner,
operator, or employee of a health
care facility where the patient is
receiving care, unless the physician
would also qualify as a surrogate
decision-maker under the law.13
Whether or not we should loosen
our laws to allow for this option
raises normative questions about
whether physicians should be given
the authority to both treat and act as
agent.
Unfortunately, our current
framework for health care decision
making seems to be one in which
we expect that one size will fit
all. In the 1960s, we rejected the
paternalism model and adopted
autonomy. Perhaps, at least in the
context of decision-making for
patients who lack capacity, we
need a scheme that allows for both
— permitting the patient to choose
autonomy or paternalism.
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Clinical Cancer Research
Cont. from page 4

the advancement of knowledge is
one that I personally find daunting
at times, as I find it difficult to tell a
patient that they will be “used” to
evaluate toxicity and dose limitations;
however Phase I trials have resulted
in effective treatments and wondrous
advances in cancer care. The bottom
line, however, is that the person in
front of me is, and will always be,
front-and-center my primary interest.
So, how can this dilemma be
resolved? The first premise must be
that there is no way around it: Phase
I trials must be performed in order
to make cancer treatment advances
for the next generation. There must
10 Mid-Atlantic Ethics Committee Newsletter

be a paradigm change that informed
consent is not the ethical litmus test
of the Phase I trial. There is no one
true ethical rationalization for the
Phase I trial, but rather a simple set of
criteria that, if followed, will assist in
rendering ethical the Phase I trial: (1)
those designing and administering the
study do so as carefully as possible so
as to minimize harm and maximize
efficacy; (2) those providing care and
information for the study subject do
their very best to inform them that
they are being studied for side effects
and toxicity primarily, and that the
likelihood of their cancer responding
to the treatment is less than 50%, with
cure nearly impossible; (3) patients

with advanced cancer must be
informed of the alternative to clinical
trials, which is supportive care that
may translate to better quality of
life, and they must be told clearly
that they have a choice in the matter.
Finally, the physician-scientists
must try to resolve their conflicts of
interest in favor of the person in front
of them—their patient.
Laurie Lyckholm, M.D.
Associate Professor and
Program Director
Hematology/Oncology and
Palliative Medicine
Virginia Commonwealth University
School of Medicine
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Consortium for Higher Education. Speaker: Arthur Caplan, Ph.D. Holy Family University, 9801
Frankford Ave., Philadelphia, PA. Contact: (215) 572-8543, or register online at www.sepche.org.

23	
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Countries. Speaker Nancy Kass, Sc.D. Sponsored by the Johns Hopkins Berman Bioethics Institute,
“Grounds for Discussion.” Evergreen Coffee House at 501 West Cold Spring Lane, Baltimore.
For more information on this event, please visit www.hopkinsmedicine.org/bioethics/events/
GrandRounds.pdf, or contact Stephanie Davis at stdavis@jhsph.edu or 410-516-8570. RSVP
Requested.

25

12 Noon (free) Grand Rounds: Bioethics, Genetic Testing and Genomic Medicine. Sponsored by
the Shady Grove Adventist Hospital Ethics Committee. Oak Room, Weinschel Education Center,
Shady Grove Adventist Hospital, Rockville, MD. Contact: paul@vannice.com.
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(8:00 a.m. – 4:30 p.m.) The Future of Hospital Ethics. The Orange Tree Golf Resort, 10601 N.
56th St., Scottsdale, AZ. Contact: 602-445-4356, e-mail edservices@azhha.org, or visit www.azhha.
org/public/education and click on “Program Calendar.”
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(4:30 p.m. – 7:15 p.m.) Money and Medicine: Bedside Ethics of the Medical Marketplace. Cosponsored by the Maryland Health Care Ethics Committee Network at the University of Maryland
School of Law, the Health Facilities Association of Maryland, and Med-Chi. Greater Baltimore
Medical Center (GBMC), Towson, Maryland. For more information, visit www.law.umaryland.edu/
mhecn, call Lu Ann Marshall at (410) 706-4128, or MHECN at (410) 706-4457, e-mail MHECN@
law.umaryland.edu.
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(7:30 a.m.) Giving and Receiving Bad News, The Sister Margaret James Lecture. Speaker Rhonda
Fishel, MD. St. Agnes Hospital, 900 Caton Avenue, Baltimore, MD. Registration and breakfast at
7:00 a.m. in the Alagia Auditorium. Lecture at 7:30 a.m. RSVP to Carol Webb at 410-368-3412 by
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